Jefferies Group LLC restated their buy rating on shares of Agilent Technologies, Inc. (NYSE:A) in a research report released on Wednesday morning. They currently have a $66.00 target price on the medical research company’s stock.
Several other equities research analysts have also issued reports on the company. Barclays PLC reissued a buy rating and set a $67.00 price objective on shares of Agilent Technologies in a research note on Wednesday, July 19th. Wells Fargo & Company raised Agilent Technologies from a market perform rating to an outperform rating and lifted their price target for the stock from $42.92 to $60.73 in a research note on Wednesday, July 12th. Deutsche Bank AG reaffirmed a buy rating and set a $66.00 price target on shares of Agilent Technologies in a research note on Thursday, June 22nd. BidaskClub upgraded Agilent Technologies from a buy rating to a strong-buy rating in a report on Sunday, August 6th. Finally, Morgan Stanley reiterated an overweight rating on shares of Agilent Technologies in a report on Monday, July 10th. Two research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Agilent Technologies presently has an average rating of Buy and a consensus price target of $60.12.
Shares of Agilent Technologies (A) traded up 1.30% during trading on Wednesday, hitting $59.33. The stock had a trading volume of 1,511,552 shares. The company has a market capitalization of $19.06 billion, a price-to-earnings ratio of 33.35 and a beta of 1.30. The firm has a 50 day moving average of $60.10 and a 200 day moving average of $55.69. Agilent Technologies has a 1-year low of $42.92 and a 1-year high of $61.84.
Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Monday, May 22nd. The medical research company reported $0.58 EPS for the quarter, beating the Zacks’ consensus estimate of $0.48 by $0.10. The company had revenue of $1.10 billion during the quarter, compared to the consensus estimate of $1.05 billion. Agilent Technologies had a return on equity of 16.49% and a net margin of 13.41%. Agilent Technologies’s revenue was up 8.1% on a year-over-year basis. During the same period last year, the business posted $0.44 earnings per share. Analysts expect that Agilent Technologies will post $2.23 EPS for the current fiscal year.
WARNING: This news story was originally published by Stock Observer and is owned by of Stock Observer. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.thestockobserver.com/2017/08/12/agilent-technologies-inc-a-earns-buy-rating-from-jefferies-group-llc.html.
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, July 26th. Shareholders of record on Monday, July 3rd were issued a dividend of $0.132 per share. This represents a $0.53 annualized dividend and a dividend yield of 0.89%. The ex-dividend date was Thursday, June 29th. Agilent Technologies’s dividend payout ratio (DPR) is presently 29.78%.
In other news, insider Patrick Kaltenbach sold 5,000 shares of Agilent Technologies stock in a transaction on Thursday, July 13th. The shares were sold at an average price of $61.26, for a total transaction of $306,300.00. Following the completion of the sale, the insider now directly owns 45,138 shares in the company, valued at $2,765,153.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Michael R. Mcmullen sold 50,000 shares of Agilent Technologies stock in a transaction on Tuesday, May 23rd. The stock was sold at an average price of $59.86, for a total transaction of $2,993,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 112,608 shares of company stock valued at $6,737,509.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Cribstone Capital Management LLC boosted its position in Agilent Technologies by 2.3% in the first quarter. Cribstone Capital Management LLC now owns 2,359 shares of the medical research company’s stock worth $125,000 after buying an additional 54 shares during the last quarter. Trust Co. of Vermont boosted its stake in Agilent Technologies by 8.1% in the first quarter. Trust Co. of Vermont now owns 2,743 shares of the medical research company’s stock worth $145,000 after buying an additional 205 shares in the last quarter. Acrospire Investment Management LLC boosted its stake in Agilent Technologies by 92.3% in the second quarter. Acrospire Investment Management LLC now owns 2,500 shares of the medical research company’s stock worth $148,000 after buying an additional 1,200 shares in the last quarter. Parallel Advisors LLC boosted its stake in Agilent Technologies by 5.3% in the second quarter. Parallel Advisors LLC now owns 2,623 shares of the medical research company’s stock worth $157,000 after buying an additional 131 shares in the last quarter. Finally, CENTRAL TRUST Co boosted its stake in Agilent Technologies by 15.3% in the first quarter. CENTRAL TRUST Co now owns 2,994 shares of the medical research company’s stock worth $158,000 after buying an additional 398 shares in the last quarter.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.